Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Clinical and Molecular Hepatology · 01.07.2024 · 30 (3) · 539-560
DOI: 10.3350/cmh.2024.0060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2024. Verfasst von Mehrangiz Dezhbord und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Hepatitis B virus, Trans-Activators, Virus Replication, Nuclear Proteins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background/Aims: The major histocompatibility class II (MHC II) transactivator, known as CIITA, is induced by Interferon gamma (IFN-γ) and plays a well-established role in regulating the expression of class II MHC molecules in antigen-presenting cells.
Methods
Primary human hepatocytes (PHH) were isolated via therapeutic hepatectomy from two donors. The hepatocellular carcinoma (HCC) cell lines HepG2 and Huh7 were used for the mechanistic study, and HBV infection was performed in HepG2-NTCP cells. HBV DNA replication intermediates and secreted antigen levels were measured using Southern blotting and ELISA, respectively.
Results
We identified a non-canonical function of CIITA in the inhibition of hepatitis B virus (HBV) replication in both HCC cells and patient-derived PHH. Notably, in vivo experiments demonstrated that HBV DNA and secreted antigen levels were significantly decreased in mice injected with the CIITA construct. Mechanistically, CIITA inhibited HBV transcription and replication by suppressing the activity of HBV-specific enhancers/promoters. Indeed, CIITA exerts antiviral activity in hepatocytes through ERK1/2-mediated down-regulation of the expression of hepatocyte nuclear factor 1α (HNF1α) and HNF4α, which are essential factors for virus replication. In addition, silencing of CIITA significantly abolished the IFN-γ-mediated anti-HBV activity, suggesting that CIITA mediates the anti-HBV activity of IFN-γ to some extent. HBV X protein (HBx) counteracts the antiviral activity of CIITA via direct binding and impairing its function.
Conclusions
Our findings reveal a novel antiviral mechanism of CIITA that involves the modulation of the ERK pathway to restrict HBV transcription. Additionally, our results suggest the possibility of a new immune avoidance mechanism involving HBx.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea.
- Department of Pharmacology, School of Medicine, Konkuk University, Seoul, Korea.
- Department of Surgery, Division of HBP Surgery and Liver Transplantation, College of Medicine, Korea University, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
- Korea National Institute of Health
Zitieren
APA
Dezhbord, M., Kim, S. H., Park, S., Lee, D. R., Kim, N., Won, J., Lee, A. R., Kim, D. S., & Kim, K. H. (2024). Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction. Clinical and Molecular Hepatology, 30(3), 539-560. https://doi.org/10.3350/cmh.2024.0060
Vancouver
Dezhbord M, Kim SH, Park S, Lee DR, Kim N, Won J, et al. Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction. Clinical and Molecular Hepatology. 2024;30(3):539-560. doi:10.3350/cmh.2024.0060
BibTeX
@article{Dezhbord2024,
author = {Dezhbord, Mehrangiz and Kim, Seong Ho and Park, Soree and Lee, Da Rae and Kim, Nayeon and Won, Juhee and Lee, Ah Ram and Kim, Dong-Sik and Kim, Kyun-Hwan},
title = {Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction},
journal = {Clinical and Molecular Hepatology},
year = {2024},
volume = {30},
number = {3},
pages = {539--560},
doi = {10.3350/cmh.2024.0060}
}
EUVIMED